Asset
Zerlasiran
Silence Therapeutics Plc American Depository Share
Revenue
No revenue reported in loaded filings.
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05537571 | phase2 | completed | 2022-12-13 | 2024-01-11 | Silence Therapeutics plc | Evaluate SLN360 in Participants With Elevated Lipoprotein(a) at High Risk of Atherosclerotic Cardiovascular Disease Events |
| NCT04606602 | phase1 | completed | 2020-11-18 | 2023-08-23 | Silence Therapeutics plc | Study to Investigate Safety, Tolerability, PK and PD Response of SLN360 in Subjects With Elevated Lipoprotein(a) |
FDA applications (0)
This company has no applications containing this asset.